FDA warns GLP-1 drugs may pose risk of rare condition that causes vision loss
The risk appears small and data is mixed, but FDA wants patients to be aware.
The Food and Drug Administration has issued a warning that GLP-1 receptor agonist drugs, including Ozempic, Wegovy, Zepbound, and Mounjaro, may raise the risk of a rare eye condition known as non-arteritic anterior ischemic optic neuropathy, or NAION. This condition arises from reduced blood flow to the optic nerve, resulting in swelling, cell death, and ultimately, permanent vision loss.
The exact mechanism by which these drugs could trigger NAION remains unclear. Despite its rarity, occurring in two to 10 individuals per 100,000 in the general population, the difficulty in determining a definitive link is amplified by the common risk factors associated with GLP-1 drug usage. These factors include diabetes, cardiovascular disease, hypertension, hypercholesterolemia, metabolic syndrome, and obstructive sleep apnea.
Written by urgent.news from Ars Technica Health's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
This story
This is one outlet's version. Read the fullest account.
- FDA adds rare vision-loss warning to popular GLP-1 drugs winnipegfreepress.com
- STAT+: FDA warns GLP-1 drugs carry potential risk of rare eye condition statnews.com
- GLP-1 drugs show lower obesity-related cancer risk than insulin, but not all diabetes treatments medicalxpress.com
- FDA warns of rare 'eye stroke' risk from GLP-1 drugs thehill.com
- FDA warns of rare vision-loss side effect from GLP-1 drugs cbsnews.com
- FDA adds rare vision-loss warning to popular obesity, diabetes drugs thehindu.com
- FDA warns of vision loss risk linked to popular GLP-1 drugs cnbc.com
